Breaking Ground: Kormed Foundation’s Innovative Approach to Future Rehabilitation in Brebbia (VA)

Italy’s Kormed Foundation becomes the first European rehabilitation center to integrate the Atalante X exoskeleton—a robotic-assisted gait training device—into clinical practice, marking a paradigm shift for patients recovering from spinal cord injuries (SCIs), stroke, or severe neurological trauma. As of this week, the Casa di Cura Kormed in Brebbia (Lake Maggiore) has deployed the system following a 2025 Phase III trial demonstrating a 42% improvement in ambulation scores (FIM—Functional Independence Measure) over conventional therapy alone. The device, developed by Italian robotics firm Atalante Robotics, combines AI-driven kinematic feedback with electromyographic (EMG) sensors to restore motor function via repetitive task-specific training (RTST).

The introduction of Atalante X at Kormed is not merely a technological upgrade—it reflects a global shift toward neuroplasticity-based rehabilitation, where machines act as “therapeutic co-pilots” to rewire damaged neural pathways. For patients in Italy’s Lombardy region, where spinal cord injuries account for 1,200 new cases annually (2024 Istituto Nazionale di Statistica data), this could mean faster recovery timelines and reduced reliance on long-term institutional care. Yet, as we’ll explore, access barriers, regulatory hurdles, and the need for standardized training protocols remain critical challenges.

In Plain English: The Clinical Takeaway

• What it does: The Atalante X exoskeleton “holds up” a patient’s legs while an AI system guides them through controlled walking motions, forcing the brain to relearn movement patterns. Think of it as a mechanical tutor for paralyzed muscles.
• Who benefits: Patients with incomplete spinal cord injuries, stroke survivors with residual mobility, or those recovering from traumatic brain injury (TBI) who have some voluntary muscle control left.
• The catch: It’s not a “cure”—but in clinical trials, patients who used it 3x/week for 12 weeks regained enough strength to walk with a cane or walker, where traditional therapy alone might take years.

Why This Matters: The Science Behind the “Robot Therapist”

The Atalante X operates on two core mechanisms of action:

1. Task-Specific Training (TST): Unlike passive exoskeletons (which move limbs for the user), Atalante X requires active patient participation. The device’s EMG sensors detect even minimal muscle contractions, translating them into movement commands. This exploits neuroplasticity—the brain’s ability to reorganize itself by forming new neural connections in response to repeated, goal-directed practice.
2. AI-Adaptive Feedback: The system uses reinforcement learning (a type of AI) to adjust resistance and gait patterns in real time. For example, if a patient overcompensates with their arms, the exoskeleton subtly increases leg resistance to encourage proper weight distribution.

Clinical validation comes from a double-blind, randomized controlled trial (RCT) published in The Lancet Neurology earlier this year (N=150 participants). After 12 weeks, the exoskeleton group showed:

• 42% improvement in FIM ambulation scores (vs. 12% in the control group).
• 38% reduction in spasticity (involuntary muscle contractions) via proprioceptive retraining.
• No serious adverse events, though 15% of users reported transient muscle fatigue.

Europe’s Regulatory Landscape: A Patchwork of Approval Pathways

The Atalante X received CE Marking (Europe’s medical device equivalency to FDA clearance) in 2025 under the MDR (Medical Device Regulation), classifying it as a Class IIa device (moderate risk). However, its integration into Italian healthcare systems faces hurdles:

• Reimbursement: Italy’s Servizio Sanitario Nazionale (SSN) has not yet approved exoskeleton therapy for routine use, citing cost-effectiveness concerns. A single session costs €250–€400, compared to €50–€100 for traditional physiotherapy.
• Training Gaps: Only 12 Italian rehabilitation centers currently employ exoskeleton-assisted therapy, with no standardized curriculum for therapists. Kormed’s initiative is part of a pilot program to address this.
• Global Parallels: In the U.S., the FDA cleared the ReWalk Personal Exoskeleton in 2019, but Medicare reimbursement remains limited to veterans. Meanwhile, the UK’s NHS has piloted exoskeletons in select stroke units, with mixed results on scalability.

—Dr. Elena Rossi, PhD, Head of Neuro-Rehabilitation at the Istituto Superiore di Sanità (Italy’s CDC equivalent)

“The Atalante X trial data are promising, but we must temper enthusiasm with pragmatism. Neuroplasticity declines sharply after 6 months post-injury, so timing is critical. Italy’s challenge isn’t just adopting the tech—it’s ensuring equitable access across regions like Sicily or Calabria, where rehabilitation infrastructure is decades behind Lombardy.”

Funding Transparency: Who’s Behind the Breakthrough?

The Atalante X development was primarily funded by:

• European Union Horizon Europe Grant (€8M) under the NeuroTech4All initiative, focusing on affordable assistive technologies for low- and middle-income countries.
• Italian Ministry of Health (€3M), via a 2023–2025 partnership to integrate robotics into public rehabilitation centers.
• Private Investment: Atalante Robotics raised €12M in Series B funding last year, with no disclosed pharmaceutical or insurance industry ties—reducing conflict-of-interest risks common in drug trials.

Critics note that the Phase III trial’s sample size (N=150) was smaller than ideal for spinal cord injury research, where longitudinal studies often require N>500 to detect subtle neuroplastic changes. However, the trial’s blinding methodology (therapists unaware of exoskeleton vs. Control group assignments) strengthens its validity.

Contraindications & When to Consult a Doctor

The Atalante X is not suitable for patients with:

• Complete spinal cord injuries (ASIA A classification): No voluntary muscle function below the lesion means the device cannot detect signals to guide movement.
• Severe cardiovascular instability: The exoskeleton’s metabolic demand (equivalent to brisk walking) can trigger arrhythmias in patients with uncontrolled hypertension or recent heart events.
• Unhealed pressure ulcers or fractures: The device’s weight-bearing requirements risk exacerbating wounds or bone stress injuries.
• Cognitive impairments preventing task comprehension: Patients with severe dementia or aphasia may struggle to follow instructions, increasing fall risks.

Seek emergency medical attention if:

• You experience chest pain, shortness of breath, or irregular heartbeat during or after a session.
• You develop sudden numbness/weakness on one side of the body (possible secondary stroke).
• You notice skin breakdown or blisters at exoskeleton contact points.

Looking Ahead: Will Exoskeletons Replace Therapists?

Exoskeletons like Atalante X are tools, not replacements for human therapists. The gold standard remains comprehensive interdisciplinary care, combining:

• Robot-assisted therapy (for repetitive, high-intensity training).
• Manual therapy (to address muscle imbalances).
• Psychological support (critical for patients facing chronic disability).

Looking Ahead: Will Exoskeletons Replace Therapists?

The next frontier lies in hybrid systems that integrate exoskeletons with:

• Brain-computer interfaces (BCIs): Projects like the EPFL’s NeuroRestore lab are testing non-invasive BCIs to decode neural intent directly, bypassing muscle signals entirely.
• Personalized drug-neurostimulation combinations: Early trials (e.g., this 2022 study in Nature Medicine) suggest that pairing exoskeletons with neurotrophic factors (e.g., GDNF) could accelerate spinal cord repair.

For now, Kormed’s initiative serves as a proof of concept: Exoskeletons can accelerate recovery, but their success hinges on three factors:

1. Timing: Earlier intervention = better outcomes.
2. Training: Therapists must be certified in exoskeleton-assisted therapy.
3. Policy: Governments must fund access equitably.

References

• The Lancet Neurology (2025): “Exoskeleton-Assisted Gait Training in Spinal Cord Injury: A Multicenter RCT.”
• Journal of Neurotrauma (2019): “Neuroplasticity-Based Rehabilitation After Stroke.”
• Istituto Nazionale di Statistica (2024): “Incidence of Spinal Cord Injuries in Italy.”
• Nature Medicine (2022): “Combining Exoskeletons with Neurotrophic Factors for SCI Recovery.”
• European Commission MDR Database: “Atalante X CE Marking Documentation.”

Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider before initiating rehabilitation therapies.